Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker ...
The cardiovascular service line, whether existing within the confines of an acute-care environment or outpatient setting ...
Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...
For any cardiology department looking to upgrade or replace its cardiovascular information system (CVIS), the main ...
Two key requirements for today’s cardiovascular information systems (CVIS) are solid integrations with both enterprise ...
Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
AliveCor Inc. announced significant milestones related to patients with atrial fibrillation (AFib) using the AliveCor Mobile ECG. Since receiving the first U.S. Food and Drug Administration (FDA) clearance for the AF Detector, an algorithm to detect atrial fibrillation in an ECG (electrocardiogram), 30 percent of AliveCor patients have received an AFib detection.
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR).
Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
St. Jude Medical Inc. announced that five-year results from the FAME trial have confirmed the long-term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone.
September 9, 2015 — The U.S. Food and Drug Administration (FDA) granted 510(k) for Philips Healthcare’s Spectral ...
St. Jude Medical Inc. announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.
Sunshine Heart Inc. announced the U.S. Food and Drug Administration (FDA) has approved an amendment to the stopping rule criteria for the company's COUNTER HF pivotal study for its C-Pulse Heart Assist System. The agency has agreed to change this protocol from "all cause" deaths to specifically, mortality associated with device, procedure or therapy.
In a new study reported in The Journal of Thoracic and Cardiovascular Surgery, researchers found a dramatic difference in cardiac function recovery with extracorporeal life support (ECLS) after cardiogenic shock depending on the nature of the attack. The results underscore the importance of mechanical circulatory support in helping the patient survive.
September 11, 2015
